AKT1 and neoplasm: To broaden the coverage of candidate pathway inhibitors, we next tested a panel of antitumor drugs targeting the RAS-MEK-ERK and receptor tyrosine kinase-PI3K-AKT-mTOR pathways in our nf1/pten-mutant melanoma model by assessing tumor-cell growth and overall survival of recipient rag2−/− fish after 6 days of treatment (Figs. 2, S8 and S9).